Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 203

Similar articles for PubMed (Select 22257045)

1.

Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials.

Han SL, Wan SL.

Int J Clin Pract. 2012 Feb;66(2):199-209. doi: 10.1111/j.1742-1241.2011.02837.x. Review.

PMID:
22257045
2.
3.

Strontium ranelate for preventing and treating postmenopausal osteoporosis.

O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005326. Review. Update in: Cochrane Database Syst Rev. 2006;(4):CD005326.

PMID:
16856092
4.

Effectiveness and safety of vitamin D in relation to bone health.

Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V.

Evid Rep Technol Assess (Full Rep). 2007 Aug;(158):1-235. Review.

5.

Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.

Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.

Bone. 2006 Dec;39(6):1268-75. Epub 2006 Aug 1.

PMID:
16884968
6.

A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study.

Kung AW, Pasion EG, Sofiyan M, Lau EM, Tay BK, Lam KS, Wilawan K, Ongphiphadhanakul B, Thiebaud D.

Curr Med Res Opin. 2006 May;22(5):929-37.

PMID:
16709314
7.

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.

Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F.

Lancet. 1997 Aug 23;350(9077):550-5.

PMID:
9284777
8.

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.

Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.

J Bone Miner Res. 2011 Mar;26(3):503-11. doi: 10.1002/jbmr.238.

PMID:
20814967
9.

Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.

Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH.

Bone. 2006 Aug;39(2):237-43. Epub 2006 Mar 24.

PMID:
16563890
10.

Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.

[No authors listed]

Prescrire Int. 2005 Dec;14(80):207-11.

PMID:
16397977
11.

Reduced risk of back pain following teriparatide treatment: a meta-analysis.

Nevitt MC, Chen P, Dore RK, Reginster JY, Kiel DP, Zanchetta JR, Glass EV, Krege JH.

Osteoporos Int. 2006 Feb;17(2):273-80. Epub 2005 Sep 2. Review.

PMID:
16142502
12.

WITHDRAWN: Risedronate for the prevention and treatment of postmenopausal osteoporosis.

Cranney A, Adachi JD, Guyatt G, Papaioannou A, Robinson VA, Shea BJ, Tugwell P, Waldegger LM, Weaver B, Wells G, Zytaruk N.

Cochrane Database Syst Rev. 2007 Jul 18;(1):CD004523. Review. Update in: Cochrane Database Syst Rev. 2008;(1):CD004523.

PMID:
17636764
13.

Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.

Reginster JY.

Drugs. 2011 Jan 1;71(1):65-78. doi: 10.2165/11587570-000000000-00000. Review.

PMID:
21175240
14.

Risedronate for the prevention and treatment of postmenopausal osteoporosis.

Cranney A, Waldegger L, Zytaruk N, Shea B, Weaver B, Papaioannou A, Robinson V, Wells G, Tugwell P, Adachi JD, Guyatt G.

Cochrane Database Syst Rev. 2003;(4):CD004523. Review. Update in: Cochrane Database Syst Rev. 2006;(1):CD004523.

PMID:
14584020
15.

Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.

Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.

J Am Geriatr Soc. 2006 May;54(5):782-9.

PMID:
16696744
16.

Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis.

Vestergaard P, Jorgensen NR, Mosekilde L, Schwarz P.

Osteoporos Int. 2007 Jan;18(1):45-57. Epub 2006 Sep 2. Review.

PMID:
16951908
17.

Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.

Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.

J Assoc Physicians India. 2008 Jun;56:418-24.

PMID:
18822620
18.

Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study.

Miyauchi A, Matsumoto T, Shigeta H, Tsujimoto M, Thiebaud D, Nakamura T.

J Bone Miner Metab. 2008;26(6):624-34. doi: 10.1007/s00774-008-0871-3. Epub 2008 Nov 1.

PMID:
18979163
19.

Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.

Sugimoto T, Shiraki M, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T.

Curr Med Res Opin. 2013 Mar;29(3):195-203. doi: 10.1185/03007995.2012.761956. Epub 2013 Jan 17.

PMID:
23259702
20.

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R.

N Engl J Med. 2007 Nov 15;357(20):2028-39.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk